GSK stock slips in London as hepatitis B drug details awaited; Feb 4 results loom
GSK shares were down 0.6% at 1,879.5 pence by 1050 GMT, trading in a 1,871p to 1,886p range.
China SXT Pharmaceuticals (SXTC) stock whipsaws after AI “clinics” plan, with Friday open in focus
China SXT Pharmaceuticals Inc shares ended Thursday down 37.5% at $1.25 after swinging between $1.21 and $6.98, with volume jumping to about 109.3 million shares, Yahoo Finance data showed. The day before, the stock closed at $2.00 on roughly 115,000 shares.
AbbVie stock slides on $1.3 billion charge and outlook cut as deal chatter swirls
AbbVie shares dropped 4% on Thursday, slipping to $224.13 in after-hours trading from a previous close of $233.41, as investors digested a profit forecast reduction linked to a hefty charge.
MoonLake stock jumps after FDA feedback clears path for sonelokimab filing without new HS trials
MoonLake Immunotherapeutics shares jumped 27% to $14.34 on Thursday after the biotech said U.S. regulators supported a route to file its hidradenitis suppurativa treatment without doing more trials for the skin disease. The stock churned between $11.20 and $17.28, and roughly 24 million shares traded.
Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger
Merck & Co shares rose 1.5% to $110.20 in afternoon trading on Thursday after Wolfe Research upgraded the drugmaker, outpacing a softer health-care sector. The stock traded as high as $112.08 and as low as $107.94, while AbbVie slid about 3.9% and the S&P 500 ETF was little changed.
Pfizer stock price today: PFE ticks up after 340B court block as drug-pricing scrutiny returns
Pfizer Inc shares rose 0.3% to $25.36 on Thursday after a U.S. appeals court blocked a Trump administration pilot that would have changed how safety-net hospitals pay for some medicines. The program covered the first 10 drugs heading into Medicare price negotiations, including Pfizer and Bristol Myers Squibb’s blood thinner Eliquis, and the American Hospital Association said it would have a “devastating effect.” Reuters
Omeros stock rises in premarket after $36,000-a-vial Yartemlea price is set
Omeros Corp shares were up 0.55, or about 4%, at $14.09 in premarket trade on Thursday after the drugmaker set a $36,000 price for each single-dose vial of its newly approved Yartemlea treatment for transplant-associated thrombotic microangiopathy. “Median utilization was 8 to 10 vials per treatment course,” Chief Executive Gregory Demopulos told analysts. The stock rose 6.6% in extended trade on Wednesday. Reuters
AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down
AbbVie Inc shares slipped 1.6% to about $229.64 in premarket trading on Thursday after the drugmaker denied it was in talks to buy cancer biotech Revolution Medicines and cut its 2025 profit view. Revolution’s stock fell 11.5% in extended trading after AbbVie’s statement, Reuters reported. Investing.com+1
GSK share price slips as hepatitis B drug headline leaves investors wanting the numbers
GSK shares slipped on Thursday as investors weighed upbeat headlines on its experimental hepatitis B therapy against a lack of hard cure-rate data. The stock was down 0.9% at 1,883.5 pence in London trade, after moving between 1,880 and 1,896.5 pence and staying near the top of its 52-week range. Investing.com+1
Regeneron stock pops on BofA double-upgrade as 2026 catalysts stack up
Regeneron Pharmaceuticals shares climbed 4.6% on Wednesday after Bank of America upgraded the drugmaker to “Buy” from “Underperform” and raised its price objective to $860. Investing.com
Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes
Merck & Co shares edged down in after-hours trading on Wednesday after U.S. health officials updated the childhood immunization schedule and moved to a single dose for the human papillomavirus vaccine, a change that could pressure demand for Merck’s Gardasil shot. The stock was down about 0.2% at $108.60, after trading between $107.99 and $111.42 in the regular session. HHS.gov
AbbVie stock slips after hours after denying Revolution Medicines talks, trims 2025 profit view
AbbVie shares were down about 1% at $231.11 in after-hours trading on Wednesday after the drugmaker denied a Wall Street Journal report that it was in advanced talks to buy cancer-drug developer Revolution Medicines, saying it “is not in discussions with Revolution Medicines.” The stock had closed up 4.2% at $233.42, while Revolution shares slid 11.5% late after jumping nearly 30% earlier, with the report pointing to a valuation around $20 billion. AbbVie has spent more than $20 billion on acquisitions since 2023 as its former blockbuster Humira lost patent protection. Reuters+1
Eli Lilly stock jumps after $1.2B Ventyx buy as obesity-pill bets come into focus
Eli Lilly and Co shares climbed on Wednesday after the drugmaker agreed to buy Ventyx Biosciences in a $1.2 billion deal, pressing ahead with its push beyond blockbuster diabetes and weight-loss drugs. Lilly stock ended up 4.1% at $1,108.09, after touching $1,117.37, for a market value around $1 trillion. reuters.com
Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus
Merck & Co shares were down about 0.3% at $108.59 in afternoon trade on Wednesday after the drugmaker said it had completed its cash tender offer for Cidara Therapeutics and expected to finish the acquisition through a merger later in the day. The company said the deal will be treated as an asset acquisition, lifting 2026 research and development expense by about $9.0 billion and cutting earnings per share by roughly 30 cents in the first 12 months. “The acquisition of Cidara strengthens and complements our expanding respiratory portfolio,” Chief Executive Robert M. Davis said. Merck.com
Viasat stock slides as Evergreen signs on for Inmarsat NexusWave, CFO sale hits tape
Viasat shares fell $4.89, or about 11.3%, to $38.57 on Wednesday, a day after the stock closed at $43.46. The shares traded between $38.27 and $43.58.
Zealand Pharma stock sinks 6% in Copenhagen — what investors watch before JPM Healthcare
Shares in Zealand Pharma slid 6.1% to 405.5 Danish crowns by 11:27 a.m. CET, versus Tuesday’s close of 431.7, while Denmark’s OMXC25 index dipped about 0.4%. Zealand Pharma+1
Moderna stock slides premarket after 11% surge on flu vaccine filings — what investors watch next
Moderna shares fell 1.4% to $35.15 in premarket trading on Wednesday, after jumping 10.9% in the previous session to close at $35.66. The stock hit an intraday high of $36.26 on Tuesday, with about 20.2 million shares traded. StockAnalysis
GSK plc stock in focus as hepatitis B drug bepirovirsen clears key Phase 3 hurdle
GSK said on Wednesday its experimental chronic hepatitis B drug bepirovirsen met the primary endpoint in two phase III studies, putting it on track for regulatory submissions. The drugmaker said global filings are planned from the first quarter of 2026 after the B-Well 1 and B-Well 2 trials enrolled more than 1,800 patients across 29 countries. Chief Scientific Officer Tony Wood called the readout a “major advance”, and GSK said it defines a functional cure as losing a key viral protein and having no detectable virus DNA for at least 24 weeks after treatment ends. GSK
Johnson & Johnson stock in focus after Tecvayli-Darzalex filing, lupus drug data
Johnson & Johnson shares closed up 0.23% on Tuesday after the company announced fresh clinical and regulatory updates across oncology and immunology.
Merck stock in focus after CDC rewrites childhood vaccine schedule, puts Gardasil dosing under a microscope
Merck & Co. shares rose 1.3% to $108.87 on Tuesday, after U.S. health officials overhauled the childhood immunization schedule and shifted several vaccines away from broad, routine recommendations.
TechStock² Updates
